Based on our findings, we suggest that dual HIF-1α/HIF-2α inhibitors are potentially clinically relevant enhancers of tumor radiosensitivity, but that HIF-1α inhibitors alone may increase radiation resistance. Here, HIF1A is linked to neoplasm.